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INTRODUCTION
Studies in nuclear medicine have shed light on mo-
lecular imaging and therapeutic approaches for
oncological and nononcological conditions. Thera-
nostic approaches using the same radiopharma-
ceuticals for the diagnoses and subsequent
therapeutics of malignancies have continuously
evolved for site-directed molecular imaging and
therapy, especially in oncology. Theranostics, one
of the remarkable consequences of the Human
Genome Project, has added considerable value to
personalized medicine as diagnostic and therapeu-
tic methods are performed exclusively per personal
genotypes and phenotypes. Molecular pathways
and high-throughput omics platforms are used to
recognize and extend small molecular probes for
these conditions. Theranostic approach, however,
has long been used in clinical practice, namely in
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KEY POINTS
 Along with the considerable results of theranostics in tumoral tissues, there has been a strong push
to use this approach for nononcological diseases as well.
 Theranostics approaches may have efficient role in management of rheumatic and cardiovascular
diseases, as well as the infections including viral, bacterial and fungal.
 There is an emerging need for randomized trials to specify the factors affecting validity and efficacy
of theranostic approaches in nononcological diseases.
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